Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia
Objective: The objective of this study is to determine the prevalence of metabolic syndrome among schizophrenia patients receiving antipsychotic monotherapy in Malaysia. Method: A cross-sectional study was conducted at multiple centres between June 2008 and September 2011. Two hundred and five patie...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
2013
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/8261/1/Metabolic_syndrome_and_antipsychotic.pdf |
| _version_ | 1825719512597528576 |
|---|---|
| author | Said, M.A. Hatim, A. Habil, M.H. Zafidah, W. Haslina, M.Y. Badiah, Y. Ramli, M.A. Ananjit, S. Sapini, Y. Shah, M. Mahmud, B. Bulgiba, A. Hairi, N.N. |
| author_facet | Said, M.A. Hatim, A. Habil, M.H. Zafidah, W. Haslina, M.Y. Badiah, Y. Ramli, M.A. Ananjit, S. Sapini, Y. Shah, M. Mahmud, B. Bulgiba, A. Hairi, N.N. |
| author_sort | Said, M.A. |
| collection | UM |
| description | Objective: The objective of this study is to determine the prevalence of metabolic syndrome among schizophrenia patients receiving antipsychotic monotherapy in Malaysia. Method: A cross-sectional study was conducted at multiple centres between June 2008 and September 2011. Two hundred and five patients who fulfilled the DSM IV-TR diagnostic criteria for schizophrenia and who had been on antipsychotic medication for at least one year, were screened for metabolic syndrome. Patients receiving a mood stabilizer were excluded from the study. Metabolic syndrome was defined by using the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Treatment Panel III (ATP III) modified for Asian waist circumference. Results: In the first-generation antipsychotic (FGA) group, the highest prevalence of metabolic syndrome was among patients treated with trifluoperazine and flupenthixol decanoate (66.7 each). For the second-generation antipsychotic (SGA) group, the highest prevalence of metabolic syndrome was among patients treated with clozapine (66.7). The component with the highest prevalence in metabolic syndrome was waist circumference in both FGA and SGA groups except for aripiprazole in SGA. Conclusion: The prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic monotherapy in Malaysia was very high. Intervention measures are urgently needed to combat these problems. |
| first_indexed | 2024-03-06T05:20:53Z |
| format | Article |
| id | um.eprints-8261 |
| institution | Universiti Malaya |
| language | English |
| last_indexed | 2024-03-06T05:20:53Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | um.eprints-82612014-12-11T04:36:57Z http://eprints.um.edu.my/8261/ Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia Said, M.A. Hatim, A. Habil, M.H. Zafidah, W. Haslina, M.Y. Badiah, Y. Ramli, M.A. Ananjit, S. Sapini, Y. Shah, M. Mahmud, B. Bulgiba, A. Hairi, N.N. R Medicine Objective: The objective of this study is to determine the prevalence of metabolic syndrome among schizophrenia patients receiving antipsychotic monotherapy in Malaysia. Method: A cross-sectional study was conducted at multiple centres between June 2008 and September 2011. Two hundred and five patients who fulfilled the DSM IV-TR diagnostic criteria for schizophrenia and who had been on antipsychotic medication for at least one year, were screened for metabolic syndrome. Patients receiving a mood stabilizer were excluded from the study. Metabolic syndrome was defined by using the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Treatment Panel III (ATP III) modified for Asian waist circumference. Results: In the first-generation antipsychotic (FGA) group, the highest prevalence of metabolic syndrome was among patients treated with trifluoperazine and flupenthixol decanoate (66.7 each). For the second-generation antipsychotic (SGA) group, the highest prevalence of metabolic syndrome was among patients treated with clozapine (66.7). The component with the highest prevalence in metabolic syndrome was waist circumference in both FGA and SGA groups except for aripiprazole in SGA. Conclusion: The prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic monotherapy in Malaysia was very high. Intervention measures are urgently needed to combat these problems. 2013 Article PeerReviewed application/pdf en http://eprints.um.edu.my/8261/1/Metabolic_syndrome_and_antipsychotic.pdf Said, M.A. and Hatim, A. and Habil, M.H. and Zafidah, W. and Haslina, M.Y. and Badiah, Y. and Ramli, M.A. and Ananjit, S. and Sapini, Y. and Shah, M. and Mahmud, B. and Bulgiba, A. and Hairi, N.N. (2013) Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia. Preventive Medicine. ISSN 0091-7435, DOI https://doi.org/10.1016/j.ypmed.2013.01.005 <https://doi.org/10.1016/j.ypmed.2013.01.005>. http://www.sciencedirect.com/science/article/pii/S0091743513000182 10.1016/j.ypmed.2013.01.005 |
| spellingShingle | R Medicine Said, M.A. Hatim, A. Habil, M.H. Zafidah, W. Haslina, M.Y. Badiah, Y. Ramli, M.A. Ananjit, S. Sapini, Y. Shah, M. Mahmud, B. Bulgiba, A. Hairi, N.N. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia |
| title | Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia |
| title_full | Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia |
| title_fullStr | Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia |
| title_full_unstemmed | Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia |
| title_short | Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia |
| title_sort | metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in malaysia |
| topic | R Medicine |
| url | http://eprints.um.edu.my/8261/1/Metabolic_syndrome_and_antipsychotic.pdf |
| work_keys_str_mv | AT saidma metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT hatima metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT habilmh metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT zafidahw metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT haslinamy metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT badiahy metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT ramlima metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT ananjits metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT sapiniy metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT shahm metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT mahmudb metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT bulgibaa metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia AT hairinn metabolicsyndromeandantipsychoticmonotherapytreatmentamongschizophreniapatientsinmalaysia |